Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Endometriosis (Linzagolix - Endometriosis)

Records returned : 3 (on 04 Sep 2025 at 07:44:19). Return to search results for ' Endometriosis '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
See narrative
Formulations :
  • Tablets
Restrictions / Comments:

Important

Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.

 
Links :
NFD2
SPC
Indication :
Status :
Blue
Formulations :
  • Not Specified
Restrictions / Comments:

Important

To be initiated and first 6 months treatment to be supplied by a specialist

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

 At least 1 month prescribing by the specialist prior to transfer of care.

A DXA scan is recommended after the first 52 weeks of treatment to verify that the patient does not have an unwanted degree of BMD loss, that exceeds the benefit of treatment. This DXA scan will be organised & performed by the specialist team responsible for the ongoing care of the patient

 
Links :